Emcure Pharma launches weight loss drug Poviztra in India
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The initiative is focused on a problem that continues to plague cancer outcomes in India
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Subscribe To Our Newsletter & Stay Updated